We believe Armune’s autoantibody technology has the potential to significantly improve cancer detection and enhance the outcomes of a broad range of cancer therapies.
Kalamazoo, MI (PRWEB) January 11, 2016
Armune BioScience, Inc., a medical diagnostics company that is developing and commercializing proprietary blood tests for prostate, lung and breast cancers, announced today that the company has entered into a definitive agreement with Mavericks Capital retaining them as the Company’s advisor and investment bank.
In April of 2015, Armune BioScience launched Apifiny®, the only cancer specific, non-PSA blood test for the detection of prostate cancer. Primary care clinicians and urologists in the United States have ordered over 3,000 Apifiny tests in less than nine months on the market, and the company is preparing to expand commercial operations in the US and several worldwide markets.
“We are very pleased to announce that Armune BioScience has reached an agreement to have Mavericks Capital serve as our advisor and investment bank. Mavericks Capital and its elite group of partners and life-science advisors have a remarkable track record of helping to create shareholder value in promising life-science companies,” said David Esposito, President and Chief Executive Officer of Armune BioScience. “After successfully launching Apifiny, we are prepared to scale our commercial operations in the United States and beyond. In addition, we have several promising products to develop based on our proprietary autoantibody technology. We look forward to Mavericks Capital helping us realize the full potential of our business.”
“Mavericks Capital looks forward to working with the seasoned management team and board at Armune Bioscience to raise capital in order to scale the business and develop strategic partnerships with diagnostic and pharmaceutical companies,” said John Selig, Managing Partner of Mavericks Capital. “We believe Armune’s autoantibody technology has the potential to significantly improve cancer detection and enhance the outcomes of a broad range of cancer therapies.”
Armune BioScience, Inc. is a medical diagnostics company that develops and commercializes unique proprietary technology exclusively licensed from the University of Michigan for diagnostic and prognostic tests for prostate, lung and breast cancers. Armune was incorporated as a Delaware Corporation in 2008 with corporate headquarters in Kalamazoo, MI and a research and commercial laboratory in Ann Arbor, MI.
Mavericks Capital LLC and its licensed broker dealer, Mavericks Capital Securities LLC, specializes in advising companies on M&A, capital raises and strategic partnerships across the healthcare sector. With a senior team having deep medical perspectives, core scientific knowledge and proprietary analytics, we help construct and facilitate innovative and lucrative solutions for our clients. Our practice areas include therapeutics, devices, diagnostics, services and digital health.